Advertisement

EDITORIAL COMMENT

      In this study, Seiden and colleagues
      • Seiden B
      • Weng S
      • Sun N
      • et al.
      NCCN Risk Reclassification in Black men with low and intermediate risk Prostate Cancer after genomic testing.
      assessed the utility of genomic testing to risk stratify 63 Black men with prostate cancer eligible for active surveillance (AS) at King's County Hospital Center, which serves a predominantly under-represented minority population in Brooklyn. In 63% of the cohort, genomic testing was discordant with initial risk stratification, with 28 men being reclassified to a higher National Comprehensive Cancer Network (NCCN) risk category and this was independent of a pre-biopsy prostate specific antigen (PSA) >10 ng/ml, abnormal digital rectal examination (DRE) and a high Prostate Imaging-Reporting and Data System (PI-RADS) score. In addition, 12 men were reclassified to a lower NCCN risk classification.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Seiden B
        • Weng S
        • Sun N
        • et al.
        NCCN Risk Reclassification in Black men with low and intermediate risk Prostate Cancer after genomic testing.
        Urology. 2021; (In press)
        • Washington 3rd, SL
        • Jeong CW
        • Lonergan PE
        • et al.
        Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
        JAMA Netw Open. 2020; 3e2031349
        • Dess RT
        • Hartman HE
        • Mahal BA
        • et al.
        Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
        JAMA Oncol. 2019; 5: 975-983
        • Klein EA
        • Cooperberg MR
        • Magi-Galluzzi C
        • et al.
        A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
        Eur Urol. 2014; 66: 550-560
        • Murphy AB
        • Abern MR
        • Liu L
        • et al.
        Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.
        J Clin Oncol. 2021; 39: 1660-1670
        • Leapman MS
        • Wang R
        • Ma S
        • Gross CP
        • Ma X
        Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.
        JAMA Oncol. 2021; 7: 52-58